이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Avidity Biosciences 관리

관리 기준 확인 2/4

Avidity Biosciences' CEO는 Sarah Boyce, Oct2019 에 임명되었습니다 의 임기는 4.67 년입니다. 총 연간 보상은 $ 11.14M, 5.7% 로 구성됩니다. 5.7% 급여 및 94.3% 보너스(회사 주식 및 옵션 포함). 는 $ 464.40K 가치에 해당하는 회사 주식의 0.011% 직접 소유합니다. 464.40K. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 4.8 년입니다.

주요 정보

Sarah Boyce

최고 경영자

US$11.1m

총 보상

CEO 급여 비율	5.7%
CEO 임기	4.7yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	3.6yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Recent updates

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Jun 14

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

May 19

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Mar 01

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Nov 04

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Apr 08

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Nov 17

Avidity Biosciences (NASDAQ:RNA) Is In A Good Position To Deliver On Growth Plans

Jun 07

CEO 보상 분석

Sarah Boyce 의 보수는 Avidity Biosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$229m
Dec 31 2023	US$11m	US$635k	-US$212m
Sep 30 2023	n/a	n/a	-US$202m
Jun 30 2023	n/a	n/a	-US$193m
Mar 31 2023	n/a	n/a	-US$192m
Dec 31 2022	US$5m	US$601k	-US$174m
Sep 30 2022	n/a	n/a	-US$162m
Jun 30 2022	n/a	n/a	-US$148m
Mar 31 2022	n/a	n/a	-US$128m
Dec 31 2021	US$6m	US$570k	-US$118m
Sep 30 2021	n/a	n/a	-US$96m
Jun 30 2021	n/a	n/a	-US$78m
Mar 31 2021	n/a	n/a	-US$62m
Dec 31 2020	US$823k	US$484k	-US$44m
Sep 30 2020	n/a	n/a	-US$38m
Jun 30 2020	n/a	n/a	-US$34m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$4m	US$104k	-US$25m

보상 대 시장: Sarah 의 총 보상 ($USD 11.14M )은 US 시장( $USD 6.80M ).

보상과 수익: 회사가 수익성이 없는 동안 Sarah 의 보상이 증가했습니다.

CEO

Sarah Boyce (52 yo)

4.7yrs

테뉴어

US$11,139,719

보상

Ms. Sarah Boyce serves as Independent Director of Contineum Therapeutics, Inc Since June 2024. He has been President, Chief Executive Officer and Director at Avidity Biosciences Inc. (Formerly known as Avi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Troy Wilson	Co-Founder & Independent Chairman	11.6yrs	US$260.31k	0.072% $ 3.1m
Sarah Boyce	President	4.7yrs	US$11.14m	0.040% $ 1.7m
Michael MacLean	Chief Financial & Chief Business Officer	4.1yrs	US$4.48m	0.020% $ 857.8k
W. Michael Flanagan	Chief Scientific & Technical Officer	3.4yrs	US$4.89m	0.048% $ 2.0m
Teresa McCarthy	Chief Human Resources Officer	3.8yrs	US$3.73m	0.030% $ 1.3m
Arthur Levin	Distinguished Scientist	1.3yrs	US$3.03m	0.15% $ 6.2m
Eric Mosbrooker	Chief Strategy Officer	less than a year	US$235.31k	0% $ 0
Mark Davis	Scientific Founder	12.4yrs	데이터 없음	데이터 없음
Frank McCormick	Scientific Founder & Member of Scientific Advisory Board	12.4yrs	데이터 없음	데이터 없음
Geoffrey Grande	VP of Investor Relation & Corporate Communication	less than a year	데이터 없음	데이터 없음
John Wallen	VP of Intellectual Property	no data	데이터 없음	데이터 없음
Kathleen Gallagher	Senior VP of Global Program & Head DM1	1.4yrs	데이터 없음	데이터 없음

3.6yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: RNA 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Troy Wilson	Co-Founder & Independent Chairman	11.6yrs	US$260.31k	0.072% $ 3.1m
Sarah Boyce	President	4.7yrs	US$11.14m	0.040% $ 1.7m
Arthur Levin	Distinguished Scientist	1.3yrs	US$3.03m	0.15% $ 6.2m
Mark Davis	Scientific Founder	no data	데이터 없음	데이터 없음
Frank McCormick	Scientific Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Carsten Boess	Independent Director	4.2yrs	US$245.31k	0% $ 0
Richard Heyman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Edward Kaye	Independent Director	4.8yrs	US$244.31k	0% $ 0
Eran Nadav	Observer	no data	데이터 없음	데이터 없음
Christopher Kirk	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Noreen Henig	Independent Director	4.8yrs	US$245.81k	0% $ 0
Ryan Corcoran	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 이사회: RNA 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.

Avidity Biosciences 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Avidity Biosciences, Inc. Appoints Simona Skerjanec as Board of Directors

Director recently sold US$542k worth of stock

President notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$224k worth of stock

President notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$208k worth of stock

Recent updates

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $400.9 million.

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

Avidity Biosciences, Inc. Appoints Simona Skerjanec as Board of Directors

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1

New minor risk - Insider selling

Director recently sold US$542k worth of stock

Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding

Consensus revenue estimates increase by 140%

Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor™ Trial

President notifies of intention to sell stock

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Full year 2023 earnings: EPS and revenues miss analyst expectations

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping

Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024

Avidity Biosciences Reports Positive Data Demonstrating Aoc 1044 Delivers Unprecedented Concentrations of Pmo in Muscle Following A Single Dose in Healthy Volunteers from Phase 1/2 Explore44™ Trial for Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 104%

Avidity Biosciences, Inc. announced that it expects to receive $39.999993 million in funding from Bristol-Myers Squibb Company

Consensus revenue estimates increase by 17%

Price target increased by 10% to US$40.80

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Avidity Biosciences, Inc. Presents New Data Regarding Its Clinical Study of AOC 1001 for Adults with Myotonic Dystrophy Type 1

Price target increased by 10% to US$40.80

Consensus revenue estimates increase by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Provides an Update to the Status of the Partial Clinical Hold Related to Its AOC 1001 Product Candidate

Consensus revenue estimates increase by 11%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Price target decreased by 7.8% to US$40.57

Full year 2022 earnings released: US$3.34 loss per share (vs US$2.85 loss in FY 2021)

Chief Scientific Officer exercised options and sold US$224k worth of stock

Avidity Biosciences, Inc. Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

President notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$208k worth of stock

Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

Chief Scientific Officer exercised options and sold US$831k worth of stock

Price target increased to US$44.00

Avidity Biosciences, Inc. Announces Positive AOC 1001 Phase 1/2 Marina(Tm) Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Announces Planned Explore44 Trial of AOC 1044 in Healthy Volunteers and Participants with Duchenne Muscular Dystrophy

Avidity Biosciences, Inc. Announces Phase 1/2 EXPLORE44 Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping

Avidity Biosciences Announces the Phase 1/2 Fortitude(Tm) Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences, Inc. Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

Avidity slips 20% as FDA places lead asset on partial clinical hold

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Avidity Biosciences, Inc. Enrolls Patients in the Marina(Tm) Open-Label Extension Study

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Avidity stock rises amid Chardan starting coverage with Buy

Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides

Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 2000 Growth Index

Avidity Biosciences, Inc. Supports World Facioscapulohumeral Muscular Dystrophy Day and Presents Preclinical Data from FSHD Program

Consensus forecasts updated

Price target decreased to US$45.40

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avidity Biosciences, Inc., Annual General Meeting, Jun 15, 2022

Price target increased to US$49.80

Avidity Biosciences, Inc Appoints Michael MacLean as Chief Business Officer

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind